Evidence map›Paper›PMID 39086881›Full record

ArticleJournal of the anus, rectum and colon2024

Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study).

Kozo Kataoka, Takeshi Yamada, Kentaro Yamazaki, Keita Mori, Nobuhisa Matsuhashi, Manabu Shiozawa, Takuma Iwai, Masahiro Goto, Masayoshi Yasui, Yasumasa Takii and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the anus, rectum and colon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kozo KataokaDivision of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Takeshi YamadaDepartment of Gastrointestinal Surgery, Nippon Medical School, Tokyo, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shunto, Japan.
Keita MoriDepartment of Biostatistics, Clinical Research Center, Shizuoka Cancer Center, Shunto, Japan.
Nobuhisa MatsuhashiDepartment of Gastroenterological Surgery・Pediatric Surgery, Gifu University School of Medicine, Gifu, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Takuma IwaiDepartment of Gastrointestinal Surgery, Nippon Medical School, Tokyo, Japan.
Masahiro GotoThe Second Department of Internal Medicine, Osaka Medical College Hospital, Takatsuki, Japan.
Masayoshi YasuiDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Yasumasa TakiiDepartment of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Takeshi SutoDepartment of Gastrointestinal Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Yasuyuki TakamizawaDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Naoto TakaseDepartment of Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan.
Shruti SharmaNatera, Inc., Austin, Texas, USA.
Joe EnsorNatera, Inc., Austin, Texas, USA.
Adham JurdiNatera, Inc., Austin, Texas, USA.
Minetta C LiuNatera, Inc., Austin, Texas, USA.
Masataka IkedaDivision of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The survival benefit of adjuvant chemotherapy after surgical resection of oligometastases from colorectal cancer (CRC) remains unclear. The prognostic role of circulating-tumor DNA (ctDNA) was reported recently and a risk stratification strategy based on monitoring minimal/molecular residual disease (MRD) has been proposed, however, which drug regimen is most effective for ctDNA-positive patients is unknown. Methods/Design: Oligometastatic CRC patients planning to undergo surgery were registered in this study. After metastasectomy, the registered patients were enrolled in the treatment arm, in which 8 courses of modified-FOLFOXIRI (mFOLFOXIRI; irinotecan 150 mg/m Discussion: This study will potentially identify a better treatment strategy for patients with resectable oligometastatic CRC having postsurgical ctDNA positivity, compared to the current standard of care approaches.

Indexed as

circulating tumor DNAcolorectal canceroligometastases mFOLFOXIRI

Identifiers

PMID39086881
PMCPMC11286365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.